Canada · Delayed Price · Currency is CAD DRI Healthcare Trust Earnings Call Transcripts
Fiscal Year 2025
-
Record 2025 results featured 6% income growth, margin expansion, and robust capital returns. Guidance for 2026 and beyond targets low teens EBITDA CAGR, supported by a strong pipeline, disciplined capital allocation, and continued operational improvements.
-
Q3 saw double-digit cash receipt growth, strong EBITDA margins, and a major royalty acquisition in the TED market. Portfolio diversification and disciplined capital allocation support robust cash flows, while cost optimization and new product launches position for future growth.
-
Internalization of management completed, expected to save $200M over 10 years and improve governance. Q2 2025 cash receipts were $40.2M, with Orserdu and Xolair outperforming, while Bonjour and Omidria faced reimbursement headwinds. Ectorly FDA approval adds a new growth driver.
-
Strong Q1 results featured high cash receipts and income, despite a slight year-over-year decline due to prior milestone payments. The internalization of management is expected to save over $200M in fees over 10 years, with enhanced governance and capital flexibility.
Fiscal Year 2024
-
Record financial results in 2024 included 45% growth in cash receipts and 37% higher adjusted EBITDA, driven by four major transactions and portfolio expansion. 2025 guidance anticipates further income growth, with a strong deal pipeline and improved governance and capital structure.
-
Strong year-over-year growth in cash receipts and income was driven by new transactions and portfolio expansion. Credit facilities were increased, and the company remains well-capitalized with a robust deal pipeline. Guidance updates and internalization decisions are expected in Q4.
-
Q2 2024 saw strong financial growth with 50% higher cash receipts and a 77% adjusted EBITDA margin. Leadership changes and internal control remediation followed an investigation, but business execution and capital deployment remain robust, with a positive outlook and no equity raise needed.